<DOC>
	<DOCNO>NCT01119859</DOCNO>
	<brief_summary>This randomize , blind , parallel arm study evaluate efficacy safety tocilizumab ( RoActemra/Actemra ) versus adalimumab monotherapy patient rheumatoid arthritis intolerant methotrexate continue treatment methotrexate consider inappropriate . Patients randomize receive either tocilizumab 8 mg/kg intravenously ( iv ) every 4 week plus placebo subcutaneously ( sc ) every 2 week , adalimumab 40 mg sc every 2 week plus placebo iv every 4 week . Treatment anticipate last 24 week . With regard blind , study nurse unblinded due nature treatment administration , investigator patient remain blinded .</brief_summary>
	<brief_title>A Study Tocilizumab ( RoActemra/Actemra ) Versus Adalimumab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult patient , ≥ 18 year age . Rheumatoid arthritis &gt; 6 month duration . Intolerant methotrexate continue treatment methotrexate consider inappropriate . All diseasemodifying antirheumatic drug ( DMARD ) withdrawn prior receive study drug . Weight ≤ 150 kg . Major surgery ( include joint surgery ) within 12 week prior baseline plan major surgery within 6 month baseline . History current inflammatory joint disease rheumatoid arthritis ( RA ) . Treatment biologic agent time prior baseline . Intraarticular parenteral corticosteroid ≤ 4 week prior baseline . Active current infection history recurrent bacterial , viral , fungal mycobacterial infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>